Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

Ovarian Cancer With Malignant Ascites Clinical Trial

Status Recruiting

Clinical Trial Summary

To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ascites
• Ovarian Cancer With Malignant Ascites
• Ovarian Neoplasms

• NCT number: NCT01838538
• Study type: Interventional
• Source: Chinese PLA General Hospital
• Contact: Nan Du, PhD
• Phone: 861068989123
• Email: dunan05@yahoo.com.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: June 2011